Higher TMB significantly predicts favorable outcomes to PD-1/PD-L1 blockade in NSCLC as well as small-cell lung tumors, implying that comprehensive genomic profiling may result in patient benefit. This evidence concerns the gene CD274 and non-small cell lung carcinoma.